{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Batsa Debrah L"],"funding":["Bill and Melinda Gates Foundation"],"pagination":["933-943"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7428389"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(4)"],"pubmed_abstract":["<h4>Background</h4>Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone.<h4>Methods</h4>This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocerco"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial."],"pmcid":["PMC7428389"],"funding_grant_id":["OPPGH5342"],"pubmed_authors":["Dubben B","Batsa Debrah L","Klarmann-Schulz U","Gruetzmacher B","Fimmers R","Weil G","King CL","Hoerauf A","Debrah AY","Osei-Mensah J","Mubarik Y","Fischer K","Ayisi-Boateng NK","Nadal J","Kazura JW","Ricchiuto A","Konadu P"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial.","description":"<h4>Background</h4>Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone.<h4>Methods</h4>This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocerco","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-06-06T22:59:17.837Z","creation":"2025-04-05T13:50:50.544Z"},"accession":"S-EPMC7428389","cross_references":{"pubmed":["31536624"],"doi":["10.1093/cid/ciz889"]}}